Hook / Thesis
Centene is bruised but not broken. The shares trade at multi-year lows relative to free cash flow and sales even after recent rallies, and the company's $7.1 billion of free cash flow gives management scope to prioritize margin repair over membership growth. At current levels the market is pricing the company more for a growth collapse than for a managed rebase backed by meaningful cash generation.
We think a disciplined long position makes sense here: market-set Medicare tailwinds and active cost cuts should reduce near-term earnings variability while balance-sheet and cash flow metrics provide downside support. This is a tactical, long-term (180 trading days) trade that buys a visible path to normalized profitability at a price that already discounts a difficult operating backdrop.
Business primer - why the market should care
Centene operates as a large managed-care operator across Medicaid, Medicare Advantage, and commercial lines, with an attached set of pharmacy and specialty services. The Medicaid business is capital intensive on claims management and membership; Medicare Advantage is a higher-margin, rate-sensitive book that benefits from favorable CMS adjustments.
The market watches three levers closely: membership trends, the health benefits/claims ratio, and cash flow. Recent headlines show membership pressure in the ACA marketplace and some Medicaid churn, but Centene remains a scale operator with diversified government contracts and strong cash generation.
What the numbers say
- Revenue: Centene reported $49.73 billion for the fourth quarter 2025, a top-line that demonstrates the company's scale and underwriting exposure.
- Membership: Total membership fell from 27.9 million to 26.27 million year-over-year, and marketplace membership declined from 5.626 million to 3.582 million (reported in mid-2026) - a meaningful headwind to top-line growth and risk pool mix.
- Free cash flow and valuation: Free cash flow sits at roughly $7.11 billion. Market cap is approximately $33.4 billion and enterprise value is about $28.48 billion. That implies a price-to-free-cash-flow near 4.7 and an EV/sales multiple of ~0.14 - levels that imply significant downside already priced in.
- P&L and capital structure: The price-to-earnings metric is negative due to cyclical earnings pressure, while debt-to-equity of ~0.76 keeps leverage moderate for the sector. Return on equity and assets are negative currently, reflecting the hit to margins and earnings.
Valuation framing
Centene is trading at a low multiple to cash flows and sales: price-to-sales around 0.17 and price-to-free-cash-flow around 4.7. For a large managed-care company with government-contracted revenue, those metrics are eye-catching. Enterprise value to EBITDA sits near 9.9, which is not expensive for a regulated, high-cash-flow business that can compress temporarily.
Qualitatively, the market is weighting near-term membership and claims uncertainty heavily. Historically, large insurers trade at higher multiples when margins normalize. This trade assumes the market gradually reassigns a higher multiple as margins stabilize and growth tailwinds (Medicare rate increases, improved risk scores, and cost controls) materialize.
Catalysts
- CMS Medicare Advantage rate validation - on 04/07/2026 CMS announced a stronger-than-expected boost to 2027 capitation rates; durable rate improvements reduce earnings volatility in the MA book.
- Cost actions and workforce adjustments - the company initiated voluntary separation programs to align headcount and costs (reported 06/16/2026), which should drive margin improvement if executed cleanly.
- Stabilization in marketplace membership - any evidence that marketplace churn is slowing or that retention programs are working will materially improve near-term revenue visibility.
- Continued free cash flow delivery - consistent FCF (recently ~ $7.11B) will allow the company to invest in growth, deleverage opportunistically, or return capital, all of which are value-accretive catalysts.
Trade plan (actionable)
Direction: Long
Entry price: $66.50
Target price: $75.00
Stop loss: $61.00
Horizon: long term (180 trading days) - we expect margin repair and the re-rating process to play out over multiple quarters. This horizon gives time for CMS rate effects, cost actions, and membership stabilization to show up in the income statement and guidance.
Rationale: Entry near $66.50 buys the stock at a P/FCF that already prices in a materially weaker operating environment. The $75 target assumes a partial re-rating toward mid-single-digit FCF multiples and some recovery of margin/leverage confidence. The $61 stop sits under the 50-day EMA and provides a hard technical cut-off should downward momentum re-accelerate.
Technical and sentiment context
On technicals, the price is above the 50-day simple moving average ($63.00) and roughly tracking the 20-day average ($66.32), with RSI around 54 - neutral. MACD shows bearish momentum in the short run, and short interest has been variable but meaningful (recent settlements show ~15 million shares short). That combination suggests upside is possible but the path may be choppy; use the stop to control losses.
Risks and counterarguments
- Membership erosion persists - Continued declines in Medicaid or marketplace membership would shave revenue and could force more aggressive margin allowances. If the company cannot stabilize enrollment, earnings will remain pressured.
- High health benefits / claims ratio - The company has faced a high health benefits ratio (reported around 94.3 in the latest update). If claims normalize higher than management expects, margin improvement could be delayed or reversed.
- Regulatory and reimbursement risk - Changes in CMS policy, state Medicaid funding, or risk-adjustment rules could materially affect revenue in government-contracted lines, even with favorable short-term rate action.
- Execution risk on cost cuts - Workforce reductions and other efficiencies can be disruptive; if cost actions reduce service quality or increase administrative friction, churn could accelerate.
- Market sentiment and multiple compression - If the market re-prices the managed-care sector more aggressively, Centene could see its low multiples get even lower, limiting upside even if operational metrics improve.
Counterargument: One could argue that the market is appropriately discounting a prolonged secular decline in ACA marketplace volumes and that management's margin-first stance will fail to offset revenue erosion. In that view, cash flows will shrink and multiples will compress further, making a long position premature. This is plausible and is precisely why the trade uses a tight stop and a longer time horizon to allow operational improvements to prove out.
What would change our mind
We would reassess or close the long thesis if any of the following occur before our time horizon plays out:
- Membership declines accelerate materially beyond recent trends or guidance revisions point to permanent loss of core blocks.
- Health benefits ratio continues to deteriorate with no sign of improvement from cost actions or pricing adjustments.
- Company guidance is lowered materially (e.g., FCF or adjusted EPS guidance cut meaningfully below current expectations) or liquidity metrics weaken.
Conclusion
Centene is a defensive-style, cash-generative healthcare operator that is currently trading at depressed multiples relative to its free cash flow and sales. The combination of Medicare rate tailwinds, active cost initiatives, and a sizable FCF cushion argue for a measured long exposure. This trade is not blind optimism - membership trends and claims mix are real risks - but on a 180-trading-day horizon the risk-reward looks asymmetric: downside is capped by valuation and cash, while upside can be realized if margins and membership stabilize.
Entry at $66.50, target $75.00 and stop $61.00 gives a clear, executable plan to participate in re-rating while controlling downside should execution or macro conditions deteriorate.